BHS

Belgian Hematology Society

38th General Annual Meeting of the Belgian Hematology Society

February 3-4, 2023

Face to face Meeting

www.bhs.be

MPN / CML subcommittee

BHS

BHS GAM committee meeting: February 2th 2023

Presentation: Timothy Devos

BHS
Belgian Hematology Society

38th General Annual Meeting of
the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting

MPN / CML subcommittee: who are we?

members

Christine Schuermans
Samantha Benghiat
Dominiek Mazure
Koen Van Eygen
Philippe Lewalle
Violaine Havelange
Benjamin Bailly
Nikki Granacher
Lien Deleu
Frédéric Lambert
Adriano Salaroli
Natalie Put
Mélanie Vaes
Marie Gicart
Gaëlle Vertenoeil

Timothy Devos
(chairman)

New member in 2022-2023:

Julien Devreux (CHU Mont-Godine Namur)

BHS
Belgian Hematology Society

38th General Annual Meeting of
the Belgian Hematology Society

February 3-4, 2023
Face to face Meeting

MPN / CML subcommittee: organisation and objectives

- 14 hospitals represented (both university and non-university hospitals)
- 3 meetings/year (1 onsite (Woluwe) and 2 online)
- cooperation with colleagues of clinical biology, genetics, Belgian Cancer registry, RIZIV/INAMI (ComPerMed: input diagnostic flows MPN), patient groups, …

<u>Topics discussed</u>:

- education
- recommendations/guidelines
- translational studies, registries
- clinical trials

- reimbursement issues
- discuss complex MPN and CML patient cases
- share past congresses (take home messages …)

MPN / CML subcommittee - 2022: more specifically

- CML in adolescents and young adults (AYA): Fi LMC study
- project: Belgian asciminib-registry (CML)
- translational research: project Professor Stefan Constantinescu and Professor Havelange: genetic studies on transition MPN → AML.
- translational research: project Professor Pierre Heimann: myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, -B, FGFR1 or JAK2.

MPN / CML subcommittee - 2022: more specifically (2)

- **interferon for Belgian MPN patients:**
  - **Pegasys®** (peginterferon-α): until 2021, sample program, now stop
  - advice: request Pegasys via BSF/FSS
  - BHS MPN subcommittee wrote to company to offer medical advice to start the reimbursement process in Belgium (indication in several MPN and pregnant CML patients).

  - **Besremi®** (ropeginterferon-α)
  - trials in PV patients

MPN / CML subcommittee: future projects

2023: writing of the BHS guidelines on eosinophilic disorders

Important unmet need for such guidelines:

- 1) firstly, never BHS guidelines on hypereosinophilia before. Complex topic but need for practical guidelines and recommendations.
- 2) physiopathology of eosinophilia and genetic landscape of primary eosinophilia: becomes better understood.
- 3) in addition, the anti-IL5 drug mepolizumab is now reimbursed (since 2022) for idiopathic SHE, upon request by a hematologist. We expect an increase in the need for specialist consultation for this reason.

Therefore, the BHS MPN committee kindly requests a writing grant to the President of the BHS and the BHS board

(see: application form)

MPN / CML subcommittee: future projects (2)

- **<u>continue to:</u>**
  - share our experiences and discuss complex MPN and CML cases.
  - report interesting findings and data from MPN and CML meetings.
  - meet 3 times a year
  - work together with the BHS board and the entire BHS community!
  - **welcome new and enthousiastic members !**